A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.
about
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
P2860
A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase II, randomized study o ...... in colorectal cancer patients.
@ast
A phase II, randomized study o ...... in colorectal cancer patients.
@en
type
label
A phase II, randomized study o ...... in colorectal cancer patients.
@ast
A phase II, randomized study o ...... in colorectal cancer patients.
@en
prefLabel
A phase II, randomized study o ...... in colorectal cancer patients.
@ast
A phase II, randomized study o ...... in colorectal cancer patients.
@en
P2093
P2860
P356
P1476
A phase II, randomized study o ...... in colorectal cancer patients.
@en
P2093
Fumio Kijima
Futoshi Miyazono
Hiroshi Imamura
Kenji Baba
Kouichi Kaneko
Kouki Tokuda
Kousei Maemura
Kuniaki Aridome
Masahiro Hamanoue
Masayuki Yanagi
P2860
P304
P356
10.3892/MCO.2015.724
P577
2015-12-31T00:00:00Z